Primary source: What is an Early Alert?
The FDA has classified this issue as a Class II Recall, impacting specific product lots of Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits, which Medline must now remove from sale or use.
This recall addresses a safety risk associated with the electrical connectors of the breathing circuits that could potentially lead to health complications for patients, especially vulnerable populations like neonates and infants.
Healthcare providers and distributors must immediately identify and quarantine affected products before destroying them after completing the recall actions. Compliance with FDA recall procedures is mandatory.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Healthcare providers and distributors must immediately identify and quarantine affected products before destroying them after completing the recall actions. Compliance with FDA recall procedures is mandatory.
Medline has issued a recall for specific neonatal and infant heated wire breathing circuits due to potential failures with the electrical connector that may lead to temporary or reversible health problems. Affected products must be removed from use or sale, and there are specific actions outlined for healthcare providers and distributors.
What changed: The FDA has classified this issue as a Class II Recall, impacting specific product lots of Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits, which Medline must now remove from sale or use.
Why it matters: This recall addresses a safety risk associated with the electrical connectors of the breathing circuits that could potentially lead to health complications for patients, especially vulnerable populations like neonates and infants.
Practical implication: Healthcare providers and distributors must immediately identify and quarantine affected products before destroying them after completing the recall actions. Compliance with FDA recall procedures is mandatory.
Published from the regulator source ingestion pipeline after PV impact triage.
Review and update labeling processes in accordance with the newly published safety-related changes for affected products.
MAHs must allocate resources to develop and maintain SPPs, ensuring they meet the new regulatory requirements and are ready for submission within two days upon request in crisis situations.
Implementation of new dosing schedules and an emphasis on monitoring for potential adverse reactions as outlined in the prescribing information.
Regulatory compliance processes may need updates to incorporate the new recombinant endotoxins testing method and guidelines established under the ICMRA framework.
